FHTX
HEALTHCAREFoghorn Therapeutics Inc
$4.68+0.04 (+0.86%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving FHTX Today?
No stock-specific AI insight has been generated for FHTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.27$6.95
$4.68
Fundamentals
Market Cap$275M
P/E Ratio—
EPS$-1.18
Dividend Yield—
Dividend / Share—
ROE-4.7%
Profit Margin-2.4%
Debt / Equity—
Trading
Volume85K
Avg Volume (10D)—
Shares Outstanding58.7M
FHTX News
20 articles- Foghorn Therapeutics Inc. (FHTX) reports Q1 loss, lags revenue estimatesMSN·May 8, 2026
- CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseYahoo Finance·May 7, 2026
- Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate UpdateYahoo Finance·May 7, 2026
- Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top EstimatesYahoo Finance·May 6, 2026
- Foghorn Therapeutics Inc. (FHTX) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseYahoo Finance·May 6, 2026
- Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 5, 2026
- Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual MeetingYahoo Finance·Apr 21, 2026
- Foghorn Therapeutics to Present New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual MeetingGlobeNewswire Inc.·Apr 9, 2026
- Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.6% Jump Turn into More Strength?Yahoo Finance·Apr 1, 2026
- Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Beats Revenue EstimatesYahoo Finance·Mar 11, 2026
- Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic OutlookYahoo Finance·Mar 11, 2026
- Verastem (VSTM) Reports Q4 Loss, Beats Revenue EstimatesYahoo Finance·Mar 4, 2026
- Foghorn Therapeutics to Participate in Two Upcoming Investor ConferencesYahoo Finance·Feb 24, 2026
- Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Ryan Maynard as Chief Financial OfficerYahoo Finance·Feb 23, 2026
- Foghorn Therapeutics CEO Talks Lilly-Partnered SMARCA2 Phase 1 and New Degrader Targets at ConferenceMarketbeat·Feb 14, 2026
- Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech SummitYahoo Finance·Feb 3, 2026
- Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% PremiumYahoo Finance·Jan 13, 2026
- Is Foghorn Therapeutics (NASDAQ:FHTX) In A Good Position To Deliver On Growth Plans?Yahoo Finance·Jan 12, 2026
- Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026Yahoo Finance·Jan 10, 2026
- Foghorn Therapeutics to Participate in the 8th Annual Evercore Healthcare ConferenceYahoo Finance·Nov 25, 2025
All 20 articles loaded
Price Data
Open$4.71
Previous Close$4.64
Day High$4.73
Day Low$4.62
52 Week High$6.95
52 Week Low$3.27
52-Week Range
$3.27$6.95
$4.68
Fundamentals
Market Cap$275M
P/E Ratio—
EPS$-1.18
Dividend Yield—
Dividend / Share—
ROE-4.7%
Profit Margin-2.4%
Debt / Equity—
Trading
Volume85K
Avg Volume (10D)—
Shares Outstanding58.7M
About Foghorn Therapeutics Inc
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops drugs that target genetically determined dependencies within the chromatin regulatory system. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—